Developer docs
API playgroundTry for free, no card

Search company profiles

Gurnet Point Capital

Full company profile

uuid0006qfe

Namestring
Gurnet Point Capital
Company typeenum
Private
Founded yearint
2015
Descriptiontext

Gurnet Point Capital is a private equity firm founded in 2015 and headquartered in Cambridge, Massachusetts, that invests in de-risked life sciences companies. The firm operates as the dedicated healthcare and life sciences investment arm of the B-FLEXION platform, which also fields investment partnerships across credit, real estate, and other strategies. Through B-FLEXION Life Sciences, Gurnet Point targets biopharmaceuticals, diagnostics, and innovative healthcare services with concentrated equity positions in commercial and near-commercial assets.

Its portfolio spans commercial-stage biopharma (Paratek Pharmaceuticals and its FDA-approved antibiotic Nuzyra/omadacycline; Radius Health in osteoporosis; Stallergenes Greer in allergen immunotherapy), specialty drug delivery (Corium International, including the Corplex Donepezil transdermal Alzheimer's program), diagnostics (Naveris), and specialty care services (Allergy Partners). The firm has executed multiple control and take-private transactions since 2017, including Innocoll Holdings ($209M), Corium International ($504M, later consolidated via a 2023 tender offer at $12.50 per share for ~86.21% of shares), Radius Health ($890M), and a $462M joint acquisition of Paratek Pharmaceuticals with Novo Holdings. The firm is led by founder Ernesto Bertarelli, with CFO and Operating Partner Robert Gagnon and principals Travis Read and Anne Stone.

Gurnet Point generates revenue via the standard private equity model — management fees on committed/invested capital within its dedicated life sciences mandate plus realized carried interest on successful exits — rather than through product pricing or subscription SaaS mechanics. As a privately held GP with 1–10 employees, the firm relies on co-investment partners (notably Novo Holdings) and the broader B-FLEXION operational backbone to underwrite, finance, and manage portfolio companies across geographies.

Short descriptiontext

Gurnet Point Capital is a Cambridge-based private equity firm founded in 2015 that invests in de-risked life sciences companies across biopharmaceuticals, diagnostics, and innovative healthcare services, operating as the life sciences arm of the B-FLEXION investment platform.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
1–10
akta.pro rankint
HeadquartersCambridge, United States
HQ citystring
Cambridge
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Keyword5 values
private equity, investment management, healthcare investments, life sciences investing, portfolio management
Industry1 code
PRIMARYFSANAEAA
Core Infrastructure Funds (Transport, Social, Digital, Utilities)
Financial & Insurance/Private Equity & Venture Capital/Real Assets Funds (Infrastructure, Real Estate, Energy)
SIC code1 code
  • Investors, Nec6799
Product category
Private Equity
Social media profiles1 record
GTM typeB2B
B2B
Offering typeServices
Services
Core offering1 text field

No verifiable core offering details are available in the supplied source material for Gurnet Point Capital.

Differentiator
Functional benefit
Problem solved
Product overview1 text field

Gurnet Point Capital is a private equity firm that seeds, acquires, and builds investment partnerships in transformative industries, with targeted investment across biopharma, diagnostics, and innovative healthcare services through B-FLEXION Life Sciences. The firm's portfolio consists of acquired biopharmaceutical and healthcare companies rather than a unified product platform. Key portfolio companies include Paratek Pharmaceuticals (acquired for $462M with FDA-approved antibiotic Nuzyra), Corium International (transdermal drug delivery specialist with Corplex Donepezil), Radius Health (bone health therapies), Naveris (diagnostics), Stallergenes Greer (allergen immunotherapy), and Allergy Partners (allergy treatment network). These operate as independent portfolio companies under the investment firm's umbrella.

Scale indicator3 records

Each record includes

Type, Value, Description, Source

Recent move6 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight3 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

Healthcare-focused private equity firm investing in de-risked life sciences and healthcare services companies. Direct peer given overlapping strategy of partnering with management on take-privates and growth investments in mid- and large-cap healthcare.

TypeDirect peer
Description

Healthcare-dedicated private equity firm with a long track record of biopharma, pharma services, and medtech investments. Comparable to Gurnet Point in targeting later-stage, de-risked healthcare assets with operational improvement theses.

TypeDirect peer
Description

Healthcare-focused middle-market private equity firm investing in pharma services, products, and healthcare services. Similar to Gurnet Point in its concentrated healthcare mandate and platform-building approach.

TypeDirect peer
Description

Private equity firm specializing in life sciences and healthcare, particularly pharma services and diagnostics. Comparable in scale and sector focus to Gurnet Point's B-FLEXION Life Sciences mandate.

TypeDirect peer
Description

Healthcare-focused private equity firm investing in healthcare services, life sciences, and medical products. Directly comparable as a sector specialist pursuing buyouts in similarly sized healthcare opportunities.

TypeDirect peer
Description

Life sciences-focused investment platform of Bain Capital investing across biopharma, medical devices, and diagnostics. Comparable as a scaled life sciences PE platform with diversified sub-strategies.

TypeDirect peer
Description

Healthcare investment firm with private equity, venture, and public strategies across biopharma, medical devices, and diagnostics. Comparable as a sector-dedicated investor with biopharma buyout activity similar to Gurnet Point's.

TypeBroad incumbent
Description

Large diversified alternative asset manager with a dedicated healthcare practice that invests in biopharma, healthcare services, and life sciences. Broader in scope than Gurnet Point but overlaps meaningfully in healthcare PE.

TypeBroad incumbent
Description

Growth-oriented healthcare investment strategy within KKR covering biopharma, medtech, and life sciences. Comparable as a strategic-growth healthcare investor, though operating as part of a much larger platform.

TypeDirect peer
Description

Denmark-based investment company that co-acquired Paratek Pharmaceuticals with Gurnet Point. Highly comparable as a healthcare-dedicated long-term investor with significant biopharma and life sciences activity.

Market position
Strengths4 records

Each record includes

Headline, Details, Source

Weaknesses4 records

Each record includes

Headline, Details, Source

Competitive moat4 records

Each record includes

Type, Details

Key risks5 records

Each record includes

Headline, Details, Source

Key highlights6 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

No data
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Subsidiaries2 records

Each record includes

Name, Acquired on, Relationship type, Type, Business focus

No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A5 records

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment12 records

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Gurnet Point Capital

Gurnet Point Capital is a Cambridge-based private equity firm founded in 2015 that invests in de-risked life sciences companies across biopharmaceuticals, diagnostics, and innovative healthcare services, operating as the life sciences arm of the B-FLEXION investment platform.

What Gurnet Point Capital does

Gurnet Point Capital is a private equity firm founded in 2015 and headquartered in Cambridge, Massachusetts, that invests in de-risked life sciences companies. The firm operates as the dedicated healthcare and life sciences investment arm of the B-FLEXION platform, which also fields investment partnerships across credit, real estate, and other strategies. Through B-FLEXION Life Sciences, Gurnet Point targets biopharmaceuticals, diagnostics, and innovative healthcare services with concentrated equity positions in commercial and near-commercial assets.

Its portfolio spans commercial-stage biopharma (Paratek Pharmaceuticals and its FDA-approved antibiotic Nuzyra/omadacycline; Radius Health in osteoporosis; Stallergenes Greer in allergen immunotherapy), specialty drug delivery (Corium International, including the Corplex Donepezil transdermal Alzheimer's program), diagnostics (Naveris), and specialty care services (Allergy Partners). The firm has executed multiple control and take-private transactions since 2017, including Innocoll Holdings ($209M), Corium International ($504M, later consolidated via a 2023 tender offer at $12.50 per share for ~86.21% of shares), Radius Health ($890M), and a $462M joint acquisition of Paratek Pharmaceuticals with Novo Holdings. The firm is led by founder Ernesto Bertarelli, with CFO and Operating Partner Robert Gagnon and principals Travis Read and Anne Stone.

Gurnet Point generates revenue via the standard private equity model — management fees on committed/invested capital within its dedicated life sciences mandate plus realized carried interest on successful exits — rather than through product pricing or subscription SaaS mechanics. As a privately held GP with 1–10 employees, the firm relies on co-investment partners (notably Novo Holdings) and the broader B-FLEXION operational backbone to underwrite, finance, and manage portfolio companies across geographies.

Gurnet Point Capital firmographics

Firmographics
Name
Gurnet Point Capital
Website
https://gurnetpointcapital.com
Company type
Private
Founded year
2015
Operating status
Operating
Headcount range
1–10 employees
Short description
Gurnet Point Capital is a Cambridge-based private equity firm founded in 2015 that invests in de-risked life sciences companies across biopharmaceuticals, diagnostics, and innovative healthcare services, operating as the life sciences arm of the B-FLEXION investment platform.
Ownership category
akta.pro rank

Gurnet Point Capital industry classification

Industry
Product category
Private Equity
SIC
Investors, Nec (6799)
akta.pro industry
PRIMARYFSANAEAA
Core Infrastructure Funds (Transport, Social, Digital, Utilities)
Financial & Insurance/Private Equity & Venture Capital/Real Assets Funds (Infrastructure, Real Estate, Energy)

Keywords

  • Private equity
  • Investment management
  • Healthcare investments
  • Life sciences investing
  • Portfolio management

Where Gurnet Point Capital is headquartered

Location

Headquarters

HQ city
Cambridge
HQ country
United States
HQ region
North America

Markets served

Gurnet Point Capital business model

Business model
GTM type
B2B
Offering type
Services

Gurnet Point Capital product offering

Product offering

Core offering

No verifiable core offering details are available in the supplied source material for Gurnet Point Capital.

Product overview

Gurnet Point Capital is a private equity firm that seeds, acquires, and builds investment partnerships in transformative industries, with targeted investment across biopharma, diagnostics, and innovative healthcare services through B-FLEXION Life Sciences. The firm's portfolio consists of acquired biopharmaceutical and healthcare companies rather than a unified product platform. Key portfolio companies include Paratek Pharmaceuticals (acquired for $462M with FDA-approved antibiotic Nuzyra), Corium International (transdermal drug delivery specialist with Corplex Donepezil), Radius Health (bone health therapies), Naveris (diagnostics), Stallergenes Greer (allergen immunotherapy), and Allergy Partners (allergy treatment network). These operate as independent portfolio companies under the investment firm's umbrella.

Differentiator

Problem solved

Functional benefit

Gurnet Point Capital technology and API

Technology

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Gurnet Point Capital partnerships and signals

Strategic signal

Scale indicators3 records

Recent moves6 records

Expansion highlights3 records

Gurnet Point Capital competitors and assessment

Company assessment

Direct peers

  • Patient Square Capital: Healthcare-focused private equity firm investing in de-risked life sciences and healthcare services companies. Direct peer given overlapping strategy of partnering with management on take-privates and growth investments in mid- and large-cap healthcare.
  • Avista Capital Partners: Healthcare-dedicated private equity firm with a long track record of biopharma, pharma services, and medtech investments. Comparable to Gurnet Point in targeting later-stage, de-risked healthcare assets with operational improvement theses.
  • Linden Capital Partners: Healthcare-focused middle-market private equity firm investing in pharma services, products, and healthcare services. Similar to Gurnet Point in its concentrated healthcare mandate and platform-building approach.
  • Ampersand Capital Partners: Private equity firm specializing in life sciences and healthcare, particularly pharma services and diagnostics. Comparable in scale and sector focus to Gurnet Point's B-FLEXION Life Sciences mandate.
  • Water Street Healthcare Partners: Healthcare-focused private equity firm investing in healthcare services, life sciences, and medical products. Directly comparable as a sector specialist pursuing buyouts in similarly sized healthcare opportunities.
  • Bain Capital Life Sciences: Life sciences-focused investment platform of Bain Capital investing across biopharma, medical devices, and diagnostics. Comparable as a scaled life sciences PE platform with diversified sub-strategies.
  • OrbiMed: Healthcare investment firm with private equity, venture, and public strategies across biopharma, medical devices, and diagnostics. Comparable as a sector-dedicated investor with biopharma buyout activity similar to Gurnet Point's.
  • Novo Holdings: Denmark-based investment company that co-acquired Paratek Pharmaceuticals with Gurnet Point. Highly comparable as a healthcare-dedicated long-term investor with significant biopharma and life sciences activity.

Broad incumbents

  • TPG Capital (Healthcare): Large diversified alternative asset manager with a dedicated healthcare practice that invests in biopharma, healthcare services, and life sciences. Broader in scope than Gurnet Point but overlaps meaningfully in healthcare PE.
  • KKR Health Care Strategic Growth: Growth-oriented healthcare investment strategy within KKR covering biopharma, medtech, and life sciences. Comparable as a strategic-growth healthcare investor, though operating as part of a much larger platform.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat4 records

Key risks5 records

Key highlights6 records

Customer concentration

Gurnet Point Capital social profiles

Digital presence

Gurnet Point Capital financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Gurnet Point Capital leadership team

Management profile

Number of profiles

Gurnet Point Capital subsidiaries and ownership

Company hierarchy

Subsidiaries2 records

Gurnet Point Capital funding detail

Funding detail

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Gurnet Point Capital M&A and investment

M&A and investment

M&A5 records

Investments12 records

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Gurnet Point Capital

What does Gurnet Point Capital do?

No verifiable core offering details are available in the supplied source material for Gurnet Point Capital.

Is Gurnet Point Capital a public or private company?

Gurnet Point Capital is a private company. It is classified as unknown and is currently operating.

When was Gurnet Point Capital founded?

Gurnet Point Capital was founded in 2015. It employs 1 to 10 people.

Where is Gurnet Point Capital based?

Gurnet Point Capital is headquartered in Cambridge, United States, in the North America region.

Who are Gurnet Point Capital's main competitors?

Direct peers on record are Patient Square Capital, Avista Capital Partners, Linden Capital Partners, Ampersand Capital Partners, Water Street Healthcare Partners, Bain Capital Life Sciences, OrbiMed and Novo Holdings. Broad incumbents are TPG Capital (Healthcare) and KKR Health Care Strategic Growth.

Does Gurnet Point Capital have an API?

No public API is recorded for Gurnet Point Capital.

What industry is Gurnet Point Capital in?

Gurnet Point Capital's product category is Private Equity. Its primary akta.pro industry code is FSANAEAA, Core Infrastructure Funds (Transport, Social, Digital, Utilities). Its SIC code is 6799.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
openPR.comOverview of Segmentation, Market Dynamics, and Competitive Landscape in the Pneumonia Therapeutics MarketThe pneumonia therapeutics market is forecasted to reach $18.83 billion by 2030, growing at a compound annual growth rate of 10.4%, driven by new antibiotic and antiviral drug development, rapid diagnostic adoption, antimicrobial resistance management, and expanded homecare treatment models. In June 2023, investment firms Novo Holdings and Gurnet Point Capital acquired Paratek Pharmaceuticals, Inc. for approximately $462 million, gaining its FDA-approved antibiotic Nuzyra for community-acquired bacterial pneumonia. In June 2024, Indian pharmaceutical companies Orchid Pharma Limited and Cipla Limited partnered to launch cefepime-enmetazobactam, an antibiotic combination targeting complex infections including drug-resistant pneumonia.BflexionGurnet Point Capital Completes Acquisition of Corium International, Inc.Gurnet Point Capital completed the acquisition of Corium International, Inc., following a tender offer for all outstanding shares at $12.50 per share plus contingent value rights. The transaction removes Corium from the Nasdaq stock market, making it a wholly-owned subsidiary focused on advancing its lead product candidate, Corplex Donepezil, for Alzheimer's disease treatment.FinSMEsGurnet Point Capital and Novo Holdings Acquires Paratek PharmaceuticalsGurnet Point Capital and Novo Holdings completed the acquisition of Paratek Pharmaceuticals in a transaction valued at $462 million. The Boston-based biopharmaceutical company generates annual revenues exceeding $100 million and markets the antibiotic NUZYRA for community-acquired bacterial pneumonia and skin infections. Paratek also holds global rights to develop NUZYRA for nontuberculous mycobacterial pulmonary disease and retains worldwide development rights for its acne therapy sarecycline.GlobeNewswireGurnet Point Capital and Novo Holdings A/S Complete Acquisition of Paratek Pharmaceuticals, Inc.Gurnet Point Capital and Novo Holdings completed their acquisition of Paratek Pharmaceuticals, paying $2.15 per share in cash plus a $0.85 per share contingent value right. The total consideration was approximately $462 million, including debt assumption and full CVR payment. Paratek will be delisted from NASDAQ.GlobeNewswireParatek Pharmaceuticals Announces Stockholder Approval of Acquisition by Gurnet Point Capital and Novo Holdings A/SParatek Pharmaceuticals announced that its stockholders approved the merger agreement proposal at a special meeting, to be acquired by Gurnet Point Capital and Novo Holdings A/S. Final voting results will be disclosed on Form 8-K. The company's lead product NUZYRA is an antibiotic for pneumonia and skin infections.GlobeNewswireSecond Leading Independent Proxy Advisory Firm Glass Lewis Recommends Paratek Pharmaceuticals Stockholders Vote FOR the Acquisition by Gurnet Point Capital and Novo Holdings A/SGlass Lewis and ISS both recommended that Paratek Pharmaceuticals stockholders vote for its acquisition by Gurnet Point Capital and Novo Holdings A/S. The proxy deadline is September 17, 2023, and the deal includes upfront cash and a CVR tied to NUZYRA sales.GlobeNewswireLeading Independent Proxy Advisory Firm ISS Recommends Paratek Pharmaceuticals Stockholders Vote FOR the Acquisition by Gurnet Point Capital and Novo HoldingsISS recommended that Paratek Pharmaceuticals stockholders vote for its acquisition by Gurnet Point Capital and Novo Holdings. The deal offers immediate cash value and upside participation through a CVR. Stockholders are urged to vote online by September 17, 2023.GlobeNewswireParatek Pharmaceuticals Files Definitive Proxy Statement and Letter to Stockholders in Connection with Acquisition by Gurnet Point Capital and Novo HoldingsParatek Pharmaceuticals filed definitive proxy materials and a stockholder letter for its acquisition by Gurnet Point Capital and Novo Holdings. Stockholders will receive $2.15 per share in cash plus a $0.85 contingent value right, totaling $3.00 per share, with a special meeting on Sept. 18, 2023.PR NewswireNexPoint Asset Management Sends Open Letter to the Board of Paratek Pharmaceuticals Regarding Upcoming Annual Meeting and Proposed Acquisition by Gurnet Point CapitalNexPoint Asset Management, a shareholder owning approximately 12% of Paratek Pharmaceuticals, has announced plans to withhold votes against all three board members up for election at the company's July 6, 2023 Annual Meeting, citing years of underperformance and failure to hold management accountable. The investment firm also stated it will scrutinize the proposed acquisition by Gurnet Point Capital LLC, warning it may vote against the transaction if the sale process does not justify the purchase price, particularly given that Paratek's stock has declined 86% since FDA approval of its key drug NUZYRA in October 2018. NexPoint contends the board has enriched executives at stockholders' expense and failed to diversify the drug pipeline through business development efforts.PR NewswireShareholder Alert: Ademi LLP investigates whether Paratek Pharmaceuticals, Inc. has obtained a Fair Price in its transaction with Gurnet Point Capital and Novo HoldingsAdemi LLP has announced an investigation into Paratek Pharmaceuticals' board of directors for possible breaches of fiduciary duty related to the company's pending acquisition by Gurnet Point Capital and Novo Holdings. Paratek shareholders are expected to receive $2.15 per share in cash plus a contingent value right of $0.85 per share, valuing the transaction at approximately $462 million. The law firm alleges the transaction agreement unreasonably limits competing bids and that insiders will receive substantial benefits from change of control arrangements.